Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Alabama: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 71 | 3,196 | 45% |
| 2020 | 59 | 2,875 | 49% |
| 2021 | 61 | 2,838 | 54% |
| 2022 | 59 | 2,920 | 58% |
| 2023 | 53 | 2,543 | 62% |
| 2024 | 53 | 2,415 | 64% |
| 2025 from claims | – | 2,365 2,171–2,502 | 65% |
| 2026 forecast | – | 2,343 2,062–2,704 | 66% |
| 2027 forecast | – | 2,332 1,993–2,779 | 67% |
| 2028 forecast | – | 2,319 1,935–2,840 | 68% |
| 2029 forecast | – | 2,306 1,883–2,891 | 68% |
| 2030 forecast | – | 2,291 1,835–2,935 | 69% |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 34% of the cases CMS names in Alabama; 35 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 13% inpatient hospital, 79% hospital outpatient, 8% surgery center. The share outside the hospital has moved +4 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 245 | 10,751−1.7%/yr | −1.7%/yr | 4.9 | 18% | 11,800 in 2030+1.5%/yr |
| Texas | 182 | 9,000−1.4%/yr | −1.4%/yr | 4.2 | 17% | 11,000 in 2030+3.4%/yr |
| North Carolina | 103 | 4,811−5%/yr | −5%/yr | 4.9 | 5% | 5,000 in 2030+0.6%/yr |
| Virginia | 111 | 4,758−1.7%/yr | −1.7%/yr | 4.6 | 25% | 4,870 in 2030+0.4%/yr |
| Georgia | 109 | 4,711−1.3%/yr | −1.3%/yr | 5.5 | 17% | 5,540 in 2030+2.7%/yr |
| Tennessee | 110 | 4,594−3.3%/yr | −3.3%/yr | 6.6 | 25% | 4,840 in 2030+0.9%/yr |
| South Carolina | 83 | 4,214−0.8%/yr | −0.8%/yr | 6.2 | 7% | 4,820 in 2030+2.3%/yr |
| Maryland | 91 | 3,844−0.6%/yr | −0.6%/yr | 4.4 | 68% | 4,210 in 2030+1.5%/yr |
| Oklahoma | 58 | 2,956−0.1%/yr | −0.1%/yr | 6.1 | 1% | 3,150 in 2030+1.1%/yr |
| Mississippi | 43 | 2,629−1.4%/yr | −1.4%/yr | 7.1 | 30% | 2,760 in 2030+0.8%/yr |
| Louisiana | 45 | 2,342−1%/yr | −1%/yr | 5.8 | 0% | 2,550 in 2030+1.4%/yr |
| Kentucky | 59 | 2,308−6.2%/yr | −6.2%/yr | 5.1 | 3% | 2,480 in 2030+1.2%/yr |
| Arkansas | 37 | 1,786−2.9%/yr | −2.9%/yr | 4.8 | 10% | 1,850 in 2030+0.6%/yr |
| West Virginia | 21 | 920−7.2%/yr | −7.2%/yr | 4.5 | 0% | 990 in 2030+1.3%/yr |
| Delaware | 19 | 805−2.9%/yr | −2.9%/yr | 4.7 | 31% | 860 in 2030+1.1%/yr |
| District of Columbia | 9 | 387+3.4%/yr | +3.4%/yr | 6.2 | 32% | 420 in 2030+1.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 14 | 1,324−10%/yr | −10%/yr | 3.00.6× | 18% | 940 in 2030−5.5%/yr |
| Incontinence, prolapse & sacral neuromodulation | 17 | 1,302−0.1%/yr | −0.1%/yr | 2.91.1× | 16% | 1,480 in 2030+2.2%/yr |
| Hysterectomy, hysteroscopy & ablation | 8 | 942−6.1%/yr | −6.1%/yr | 2.40.9× | 13% | 900 in 2030−0.8%/yr |
| Prostatectomy & nephrectomy | 5 | 469−7.9%/yr | −7.9%/yr | 1.21.0× | 0% | 440 in 2030−1.2%/yr |
Kidney stone management in every state, and its device makers · Every procedure market in Alabama · Every state · Compare with Florida
Boston Scientific leads with 79% of company spending on these surgeons in 2025, +42 pts on 2024.
In 2025, 3 companies reported engagement with Alabama’s surgeons worth $22K in consulting, speaking, meals and travel tied to these products, about $409 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.